Shocking. The injection of aluminium into living human tissue, including 1 day old babies.
It may take just a single injected atom delivered to the brain to start a disease process.
“How many atoms of aluminium are needed to be injected to produce a healthy baby? What is the safe number of aluminium atoms in a human infant? The answer to both questions is an absolute zero. It may take just a single injected atom delivered to the brain to start a disease process.”
When aluminium is injected into muscle (as it is with aluminium-containing vaccine adjuvants such as aluminium hydroxide or aluminium phosphate), several biological processes occur. Here’s a detailed breakdown:
1. Immediate Local Effects in the Muscle
Depot formation: Aluminium salts form an insoluble “depot” at the injection site. This slows the release of antigen into the bloodstream, prolonging exposure to the immune system. This happens in day old babies routinely injected with the hepatitis vaccine.
Irritation and inflammation: The aluminium particles are mildly irritating. They cause local cell stress and death, which releases “danger signals” (DAMPs – damage-associated molecular patterns). This triggers recruitment of immune cells. This happens in day old babies routinely injected with the hepatitis vaccine.
Innate immune activation: Macrophages, dendritic cells, and neutrophils migrate into the muscle and engulf both aluminium particles and vaccine antigens. This happens in day old babies routinely injected with the hepatitis vaccine
2. Cellular Uptake and Transport
Phagocytosis of aluminium particles: Antigen-presenting cells (APCs) engulf aluminium crystals along with the vaccine antigen. This happens in day old babies routinely injected with the hepatitis vaccine.
Migration to lymph nodes: These APCs carry antigen (and sometimes aluminium) to the draining lymph nodes, where they activate T- and B-cells. This may happen in day old babies routinely injected with the hepatitis vaccine.
Possible systemic distribution: Some animal and human studies have shown that a fraction of aluminium can move away from the injection site, accumulate in lymph nodes, and in some cases, cross the blood–brain barrier. This movement is typically slow but may be clinically relevant in susceptible individuals. This may happen in day old babies routinely injected with the hepatitis vaccine.
3. Immunological Effects
Enhanced antibody response: Aluminium adjuvants bias the immune system toward a strong antibody (Th2-type) response. This happens in day old babies routinely injected with the hepatitis vaccine.
Inflammasome activation: Aluminium can activate the NLRP3 inflammasome, leading to secretion of pro-inflammatory cytokines such as IL-1β. This happens in day old babies routinely injected with the hepatitis vaccine.
Depot + danger effect: This “antigen depot” and cell-danger signalling together explain why aluminium has been widely used as an adjuvant for decades.
4. Aluminium, Neurotoxicity, and Autism Controversy
Established science: Aluminium adjuvants increase immune response, but mainstream health agencies (WHO, CDC, EMA) hold that they are safe at the doses used in vaccines, with no proven causal link to autism. How many atoms of aluminium are needed to be injected to produce a healthy baby? What is the safe number of aluminium atoms in a human infant? The answer to both questions is an absolute zero. It may take just a single injected atom delivered to the brain to start a disease process.
Concerns raised: Some independent researchers argue that aluminium can persist in the body, accumulate in the brain, and contribute to neuroinflammation. Studies from Romain Gherardi’s group in France, for example, have shown aluminium particles inside macrophages migrating to the brain in mice.
Autism debate: The “vaccines–autism” link was originally suggested for thimerosal (ethylmercury) and later extended by some groups to aluminium. While large epidemiological studies claim to have not confirmed a link, I argue that vulnerable subgroups (e.g., with immature blood–brain barriers, mitochondrial dysfunction, or genetic susceptibility) are at risk.
5. Known Adverse Effects of Injected Aluminium
Local reactions: Pain, redness, swelling, nodules, or granulomas at the injection site. These not a minor phenomena. They are very likely the precursors to a chronic ‘inflammatory’ condition.
Macrophagic myofasciitis (MMF): A condition described in France, where aluminium-laden macrophages persist in muscle tissue for years, associated with fatigue, muscle pain, and cognitive issues.
Neurological concerns: Still debated, but low-level aluminium accumulation in the brain has been suggested as a risk factor for neurodegenerative diseases (e.g., Alzheimer’s) in some studies. However, this toxicity paradigm ignores the fact that aluminium plus protein equals hypersensitivity.
Injected aluminium acts as a depot and immune activator. Most of it stays at the injection site or in lymph nodes, but a small fraction can be transported systemically, including into the brain and peripheral nervous system. This underpins the controversy around its long-term safety, especially in relation to neurodevelopmental disorders such as autism. While mainstream bodies deny a link, mechanistic studies suggest plausible pathways (immune activation, neuroinflammation, genetic susceptibility) that require deeper research. In the meantime, it is wise say to vaccines.
References
What alum does at the injection site & how it binds antigens
Antigen adsorption onto alum via phosphate “ligand exchange” (dominant mechanism). Shows how phosphates on proteins swap with hydroxyls on Al(OH)3, plus electrostatics; adsorption strength governs persistence and release. ScienceDirect+2ScienceDirect+2
Physicochemical features of alum that shape immune response (how particle size/charge and adsorption state alter antibody titers). ScienceDirect
B. Innate immune activation & Th2 bias
Inflammasome literature—alum can activate danger-sensing pathways (NLRP3 discussed historically; later work refines/qualifies its role). ScienceDirect+2embopress.org+2
Th2 skewing and allergy models—alum is a classic Th2/IgE-promoting adjuvant in mice and in allergen immunotherapy contexts. Frontiers+2Frontiers+2
C. Distribution, biopersistence, and macrophagic myofasciitis (MMF)
Slow CCL2-dependent “Trojan horse” transport of alum-tagged macrophages from muscle to brain (mouse).Key mechanistic paper. BioMed Central
Biopersistence & brain translocation review (Gherardi/Authier group). Frontiers
MMF clinicopathology & symptomatology; persistence of Al-laden macrophages in muscle; links to fatigue/myalgias; newer 2024 data on phagocyte mitochondrial/autophagic changes. ScienceDirect+1
D. Does aluminum bind human molecules? (proteins, lipids, phosphates)
Serum binding & transport—Al binds transferrin (high-affinity) and also albumin/citrate; transferrin-receptor pathway is a plausible delivery route to tissues including brain. scispace.com+3ScienceDirect+3ScienceDirect+3
Lipid interactions—Al³⁺ binds acidic phospholipids (e.g., phosphatidylserine, PIP2), clustering them and altering membrane biophysics/signaling—direct route to “neo-epitope” display and damage signals. SpringerLink+3ScienceDirect+3Bangor University+3
Phosphorylation increases Al binding—phospho-serine chemistry points to tighter Al³⁺ interactions with phosphorylated proteins/peptides. ScienceDirect
E. Autism-relevant literature (supportive and mainstream counter-positions)
Aluminium in autism brain tissue (Mold/Exley 2018)—high Al levels in non-neuronal inflammatory cells in ASD brains (controversial but influential). ScienceDirect+1
FDA modeling of infant Al body burden (Mitkus et al., 2011)—concludes vaccine-dose Al exposure is “extremely low risk” (often cited by regulators who dont understand aluminium induced hypersensitivity and epigenetic genotoxicity). ScienceDirect+1
Regulatory statements—WHO GACVS and CDC pages summarizing the official safety view on aluminum adjuvants. However, I have no trust or confidence in these organisations. World Health Organization+2World Health Organization+2
UNBELIEVABLE!!!
(Fresh note: a 2025 regulatory-history analysis argues limits were historically not evidence-based.) ScienceDirect
“There is an urgent need for independent pharmacokinetic and toxicological studies, transparent access to proprietary adjuvant compound, and a comeback to safer alternatives such as biocompatible calcium phosphate. Updating these standards is crucial for strengthening public confidence in vaccination policies.”
When in doubt-DON’T-and always doubt vaccines.
Sparks Fly in US Senate.
Click the picture below for the link to full article.
I just thought about it that the largest organ in our body that protects us from pathogens is our skin that has many layers of protective mechanisms. So the wise medical men decided they can improve on our health by injecting vaccines, loaded with non self entities, and injecting it through the skin.
Stupidity!
Your work in pointing out the toxicity of aluminium is very important. I am afraid, though, that any revelations about adjuvant toxicity will be harnessed by those whose desire is to push the transfection injections as "the next upgrade" of vaccine technology. And as Thomas has already pointed out, it is highly likely that intramuscular injection of foreign substances across the immune boundary is a BAD IDEA period. The aluminium just makes it even worse.